ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2584

Management of Cutaneous Manifestations of Lupus Erythematosus: A Systematic Review

Jessica Fairley1, Shereen Oon 2, Amanda Saracino 3 and Mandana Nikpour 2, 1Monash University, Melbourne, Australia, 2St Vincent's Hospital, Melbourne; The University of Melbourne, Melbourne, Australia, 3University College London, London, United Kingdom

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: cutaneous lupus erythematosus and cutaneous manifestations, Lupus

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 12, 2019

Session Title: SLE – Clinical Poster III: Treatment

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Cutaneous lupus erythematosus (CLE), occurring with or without systemic lupus erythematosus (SLE), is a group of inflammatory skin diseases that can be very debilitating, causing significant psychological distress, and in some cases scarring. We sought to comprehensively present the evidence for different treatment modalities in patients with cutaneous manifestations of lupus erythematosus (LE).

Methods: Medline, Embase, Scopus and Cochrane CENTRAL were searched electronically from 1990 to March 2019, using keywords related to cutaneous lupus and synonyms and treatment. Articles retrieved were screened for relevance, including reference lists of retrieved reviews. We included clinical trials, observational studies or case series with 5 or more patients focussing on treatment of CLE, with or without SLE.

Results: The search identified 6637 studies, of which 104 were included. Each study commonly included a heterogenous mixture of CLE subtypes, with or without SLE. The 104 included studies investigated 11 different categories of treatment in 6811 patients. Treatments included topical calcineurin inhibitors (CNIs) (13 studies), sun protection (5 studies), R-salbutamol cream (2 studies), antimalarials (23 studies), synthetic disease modifying anti-rheumatic drugs (DMARDs)(10 studies), retinoids (2 studies), thalidomide/lenalidomide (22 studies), biologic therapies (12 studies), intravenous immune globulin (3 studies), laser (6 studies) and other therapies (6 studies). A suggested management algorithm based on these data, determined by disease severity, is summarised in Figure 1. General measures to be considered include smoking cessation, sun protection measures and optimisation of vitamin D levels. Moderate evidence exists for benefit with topical CNIs, particularly as a steroid sparing agent in areas at high risk of steroid complications (e.g. facial skin). There is moderate evidence for hydroxychloroquine, which is first-line in SLE patients, limited evidence to support other synthetic DMARDs, and moderate evidence supporting thalidomide but with significant risk of toxicity. Of biologic therapies, there are moderate data to support belimumab. Limited evidence exists for other therapies.

Conclusion: Many management options are available for CLE, including topical, systemic and biologic therapies, with a variable balance of efficacy and toxicity. There is a paucity of high-quality clinical trial data. Further trials are required to better understand optimal management of CLE, particularly in specific subgroups.

Figure 1: a suggested management algorithm for cutaneous lupus erythematosus


Disclosure: J. Fairley, None; S. Oon, None; A. Saracino, None; M. Nikpour, Actelion, 2, Arthritis Australia, 2, Australian Rheumatology Association, 2, Bayer, 2, BMS, 2, GSK, 2, Pfizer, 2, Roche, 2, Scleroderma Victoria and Australia, 2, St Vincent's Hospital Melbourne Research Endowment Fund, 2.

To cite this abstract in AMA style:

Fairley J, Oon S, Saracino A, Nikpour M. Management of Cutaneous Manifestations of Lupus Erythematosus: A Systematic Review [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/management-of-cutaneous-manifestations-of-lupus-erythematosus-a-systematic-review/. Accessed April 13, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/management-of-cutaneous-manifestations-of-lupus-erythematosus-a-systematic-review/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.